Vimarsana
Biggest News Aggregation in the World

Page 6 - Imux News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Imux. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Imux Today - Breaking & Trending Today

Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Hold" by Analysts - Vimarsana News

Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Hold" by Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) have been assigned a consensus rating of “Hold” from the six analysts that are covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 1-year price objective among brokerages that […]

Brokerages Anticipate Immunic, Inc. (NASDAQ:IMUX) Will Post Earnings of -$0.76 Per Share - Vimarsana News

Brokerages Anticipate Immunic, Inc. (NASDAQ:IMUX) Will Post Earnings of -$0.76 Per Share

Wall Street brokerages expect Immunic, Inc. (NASDAQ:IMUX – Get Rating) to post earnings per share of ($0.76) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Immunic’s earnings, with estimates ranging from ($0.93) to ($0.58). Immunic posted earnings per share of ($0.82) in the same quarter last year, which […]

Q2 2022 Earnings Estimate for Immunic, Inc. (NASDAQ:IMUX) Issued By Wedbush - Vimarsana News

Q2 2022 Earnings Estimate for Immunic, Inc. (NASDAQ:IMUX) Issued By Wedbush

Immunic, Inc. (NASDAQ:IMUX – Get Rating) – Wedbush raised their Q2 2022 earnings estimates for shares of Immunic in a report issued on Tuesday, May 10th. Wedbush analyst L. Moussatos now anticipates that the company will earn ($0.69) per share for the quarter, up from their prior forecast of ($0.77). Wedbush has a “Outperform” rating […]

Analysts Set Immunic, Inc. (NASDAQ:IMUX) PT at $49.25 - Vimarsana News

Analysts Set Immunic, Inc. (NASDAQ:IMUX) PT at $49.25

Shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) have been assigned an average rating of “Buy” from the six analysts that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The […]

StockNews.com Initiates Coverage on Immunic (NASDAQ:IMUX) - Vimarsana News

StockNews.com Initiates Coverage on Immunic (NASDAQ:IMUX)

StockNews.com initiated coverage on shares of Immunic (NASDAQ:IMUX – Get Rating) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the stock. Other analysts have also recently issued research reports about the stock. Wedbush reiterated a “buy” rating and issued a $61.00 price objective on shares of Immunic […]